| Code | CSB-RA878931MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to antolimab, designed to specifically target SIGLEC8 (Sialic acid-binding immunoglobulin-like lectin 8). SIGLEC8 is a cell surface receptor selectively expressed on human eosinophils, mast cells, and basophils, where it functions as an inhibitory receptor that regulates immune cell activation and survival. Upon engagement, SIGLEC8 triggers apoptosis in eosinophils and inhibits mediator release from mast cells, making it a critical regulator of allergic and inflammatory responses. This target has significant relevance in eosinophilic disorders, including eosinophilic asthma, chronic rhinosinusitis with nasal polyps, eosinophilic gastrointestinal diseases, and hypereosinophilic syndrome.
Antolimab is a non-fucosylated humanized IgG1 monoclonal antibody that binds to SIGLEC8 and has been investigated in clinical trials for eosinophil-associated inflammatory conditions. This biosimilar antibody serves as a valuable research tool for investigating SIGLEC8-mediated signaling pathways, studying eosinophil and mast cell biology, and exploring therapeutic mechanisms in allergic and eosinophilic diseases.
There are currently no reviews for this product.